BSX earnings analysis
What we found in BSX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Boston Scientific delivered Q2 revenue of $5.442 billion, up 7.5% year over year, and GAAP diluted EPS of $0.61, up 15.2% year over year, while adjusted EPS reached $0.86. Gross margin improved sharply to 70.7%, and Cardiovascular growth of 8.3% remained the principal sales driver, although Urology was nearly flat and management noted electrophysiology competition and slower WATCHMAN procedures. Liquidity and cash generation remain sound, but the approximately $14.500 billion Penumbra transaction, associated debt financing, regulatory review, litigation charges and new restructuring program are the principal incremental risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Sales growth remained solid; GAAP EPS eased sequentially
- Q2 revenue was $5.442 billion, up $381 million or 7.5% year over year; this also rose from $5.204 billion implied for Q1 2026 by the reported six-month sales of $10.646 billion. GAAP diluted EPS was $0.61, up from $0.53 a year ago but below the $0.90 implied for Q1 2026; adjusted EPS increased to $0.86 from $0.75.
- Gross margin expanded 300 basis points year over year
- Gross margin expanded to 70.7% from 67.7% in Q2 2025 and approximately 69.4% in Q1 2026. Management attributed the 300-basis-point year-over-year expansion to higher-margin mix, lower inventory charges and an $83 million IEEPA tariff refund, partly offset by foreign exchange.
- Cardiovascular and Neuromodulation led segment growth
- Cardiovascular was the largest growth contributor, with sales up $279 million to $3.624 billion, led by AGENT drug-coated balloon and Farapulse PFA. Neuromodulation grew 12.7% to $341 million and Endoscopy rose 7.6% to $793 million, while Urology grew just 1.1% to $684 million.
- Operating expense ratios improved despite R&D investment
- SG&A increased 5% to $1.803 billion but declined to 33.1% of sales from 33.9%; R&D increased 5% to $554 million while declining to 10.2% of sales from 10.4%. This indicates expense leverage while the company continues to invest in its product pipeline.
- Cash generation stayed resilient; capex intensity was modest
- First-half operating cash flow was $1.822 billion, essentially flat with $1.827 billion a year earlier. Property, plant, equipment and internal-use software spending was $372 million, equal to about 3.5% of first-half revenue of $10.646 billion; implied first-half free cash flow was approximately $1.450 billion.
- Liquidity remains adequate ahead of planned acquisition
- Liquidity included $539 million of unrestricted cash and $1.311 billion of remaining capacity under the $3.000 billion revolver after $1.689 billion of commercial paper outstanding. The company was compliant with its 4.00x maximum leverage covenant, reporting a 2.02x leverage ratio.
- No formal risk-factor updates in the 10-Q
- The filing does not update the risk factors from the most recent 10-K; Item 1A directs investors to the prior risk disclosures. However, the MD&A identifies changing tariff policies, supply-chain disruption and global conflict as ongoing uncertainties.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Penumbra deal creates material regulatory and funding risk
- The pending Penumbra acquisition is valued at approximately $14.500 billion and remains subject to regulatory clearance after the FTC issued a Second Request on March 16, 2026. Boston Scientific expects to fund approximately $11.000 billion of consideration with cash and newly issued debt, increasing execution and leverage risk.
- Procedure and competitive pressures constrain growth
- Urology sales were only $684 million, up 1.1%, as China volume-based procurement hurt the stone franchise and commercial disruption affected sacral neuromodulation. Cardiovascular growth also faced increased electrophysiology competition and a deceleration in certain WATCHMAN procedures.
- Litigation, restructuring and deal charges remain material
- Q2 GAAP results included $76 million of litigation-related charges, $42 million of restructuring and restructuring-related charges, and $92 million of acquisition/divestiture-related charges. A new global restructuring program was approved on July 21, 2026, creating potential for further charges beyond the $748 million already incurred under the prior restructuring plan.
- Tariff, supply-chain and currency volatility persist
- Management cited uncertainty around tariff rates, reciprocal trade policies, distribution costs and supply-chain disruptions. Although Q2 gross profit benefited from an $83 million tariff refund, foreign currency reduced reported quarterly sales growth by 0.5 percentage points, and currency derivatives had a $14.384 billion contract amount at June 30, 2026.
- Working capital and investment spending pressure cash
- Operating cash flow was $1.822 billion for the first half of 2026 versus $1.827 billion a year earlier despite higher sales, as higher employee and working-capital payments offset operating-income growth. Investing cash outflow increased to $2.547 billion from $1.626 billion, including $1.501 billion for investments and technology acquisitions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.61
- Gross margin
- 70.7%
- Segment
- Cardiovascular: $3.624 billion, up $279 million or 8.3% year over year (7.8% organic).
- Segment
- MedSurg: $1.818 billion, up $102 million or 5.9% year over year (5.4% organic); Endoscopy was $793 million (+7.6%), Urology was $684 million (+1.1%), and Neuromodulation was $341 million (+12.7%).
What they said about what is next.
The 10-Q MD&A does not provide a quantitative revenue or EPS outlook. Quantitative guidance was provided separately in the July 29, 2026 earnings release, rather than in this filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 1, 2026
- Boston Scientific's Q1 2026 results showed strong revenue growth of 11.6% year-over-year, reaching $5.203 billion, primarily driven by strong performance in the Cardiovascular and Neuromodulation segments. Adjusted EPS…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BSX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever